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were very scarce. Patients were distributed across SOI categories as follows: 3.9% 
mild, 51.8% moderate, 26.4% major, 17.9% severe with LOS 5.61, 10.78, 19.43 and 
34.60 days respectively. Costs for drugs ranged from € 139.82 in SOI1, € 150.26 in SOI2, 
€ 349.51 in SOI3 and € 758.41 in SOI4. Data on clinical biology amounted to € 17.13 per 
patient; on average 15 types of lab tests were used. Costs for imaging also varied 
by severity and were € 876.58, € 866.29, € 930.07 and € 1,247.45 for increasing levels of 
SOI. In total 39 different imaging tests were used covering among others functional 
measurements, radiology, Rx, CT and MRI. Total costs amounted to € 3,653 , € 5,583 , 
€ 9,489 , € 16,660 respectively. Compared to the national average these costs are 5% 
lower, mainly due to underestimation of honoraria. ConClusions: In-hospital 
costs increase with stroke severity, with the most severe patients costing 4.5 times 
more than mild patients. Bottom-up costing approximated the top-down costs.
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objeCtives: Various published sources report an incidence of symptomatic deep 
venous thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip 
or knee replacement ranging between 0.3 and 2%. This study aimed at assessing the 
in-hospital incidence of DVT/PE after major orthopaedic surgery in Belgium and the 
impact of these complications on the length of stay and hospitalization costs using 
retrospective data. Methods: The incidence of DVT/PE, the average hospitalization 
cost and the average length of stay (LOS) among patients hospitalized for hip or knee 
replacement surgery were estimated using the longitudinal IMS Hospital Disease 
Database (year 2013), including data (diagnoses, procedures, costs) on 24% of Belgian 
hospital beds. Stays were searched based on ICD-9-CM codes corresponding to hip 
replacement (81.51-81.52-81.53) and knee replacement (81.54-81.55). Occurrence 
of DVT/PE was identified with ICD-9 codes 451.1-451.2-453.4. The impact of a DVT/ 
PE complication on LOS/ cost was assessed through Wilcoxon non-parametrical 
tests. Results: 7,160 stays with hip replacement and 6,223 stays with knee replacement 
were retrieved in the database. The number of stays with a DVT/PE episode was 
respectively equal to 22 and 43 within the two subgroups, resulting in an incidence 
of 0.31% in patients with hip replacement and 0.69% in patients with knee replace-
ment. LOS of patients with a DVT/PE episode was more than twice as high after both 
hip (35.8 vs. 13.59 days; p< 0.001) and knee (31.2 vs. 9.9 days; p< 0.001) replacement. 
Hospitalization costs were also more than doubled in case of DVT/PE complication 
(€ 25,557 vs. € 12,721 in hip replacement; € 24,953 vs. € 11,298 in knee replacement; 
p< 0.001 in both cases). ConClusions: The incidences of symptomatic DVT and 
PE reported in the literature could be confirmed based on this retrospective search. 
The occurrence of DVT/PE increases dramatically both LOS and hospitalization costs 
in patients undergoing hip or knee surgery.
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objeCtives: Stroke is the second leading cause of death globally and the survivors 
are faced with long-term disability. Stroke survivors are also under the risk of recur-
rent strokes causing a potential burden on health care systems. Therefore, cost of 
stroke studies are of special importance to healthcare policy makers in order to 
predict and take precautions for stroke in their health care system. The aim of this 
study was to determine the direct economic cost of stroke from the payer perspec-
tive in Turkey. Methods: A multi-dimensional approach was used to estimate the 
direct costs of stroke in Turkey. First a large dataset covering 5 years data for 2000 
emergency department stroke admissions from a university hospital was analyzed. 
The data set covered information on the severity of the disease, socioeconomic 
status of the patients and also the medical procedures applied during the hospital 
stay. Second, the actual invoices of the same patients hospitalized in 2014 were 
analyzed. Third, a form was designed to explore the treatment strategies, medical 
procedures and resource requirements of stroke outpatients and inpatients. The 
form was applied to an expert panel and the resources determined by the panel 
were priced by the Social Security Institution’s official price list. Results: According 
to the expert panel part of the study, annual outpatient and monitoring costs were 
1.807,58 TL and intensive care and inpatient costs were 5.636,52 TL. The total annual 
cost of stroke per patient was calculated as 7.444,11 TL in Turkey. ConClusions: 
The study showed that stroke treatment had a significant economic burden on the 
healthcare budget. Outpatient and monitoring costs constituted %24 of total costs 
whereas inpatient costs constituted %76 of total costs.
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objeCtives: Venous thromboembolism (VTE) is a common disorder, with about 1 
per 1,000 people per year in the general population.Approximately two-thirds of 
cases of VTE present as deep vein thrombosis (DVT), the formation of a thrombus 
in a deep vein, usually of the lower limbs. Around one third of VTE cases present as 
pulmonary embolism (PE), occurring when dislodged thrombi (from a DVT) travel 
to the lungs. PE can cause sudden death and those who survive an episode occa-
sionally require intensive care, with recovery taking several weeks or months. The 
episodes involving inpatient care and complications could lower substantially the 
burden of diabetes.
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objeCtives: Patients with chronic heart failure (HF) in controlled trials do not 
fully represent real population followed in clinical practice. We wanted to give real 
world picture of epidemiology and hospitalization caractheristics of patients with 
HF, by analyzing administrative database of nearly 2,500,000 subjects. Evaluation 
of healthcare related costs over 1 year follow-up was performed. Methods: Data 
come from ARNO database that includes in-habitants of 7 Local Health Authorities 
of the Italian National Health Service (NHS). Patients were selected when admis-
sion for HF occurred over period of 5 years ( January 1, 2008 to December 31 2012). 
To confirm diagnosis, all patients discharged alive should be prescribed typical 
treatment for HF. Clinical characteristics co-morbidities, treatment, need for re-
hospitalization and mortality occurring in the 1st year following discharge were 
analyzed. Total costs for NHS were calculated as hospitalizations, treatments 
and out-of-hospital speciality visits or examinations. Results: 54,059 patients 
(2.2%) were admitted for HF. The great majority was admitted in Internal Medicine/
Geriatric Departments (69.5%). Of 54,059 patients, 41,413 were discharged alive and 
prescribed HF treatments. Need for re-hospitalization occurred frequently: 56.6% 
of patients was admitted at least once in 1-year following discharge, cardiovas-
cular admissions accounted for just 51% of the total hospitalizations. All-cause 1 
year mortality was 18.9%. Patient with HF generate a cost per year to NHS 7,429€ 
(11,867€ if first admission included). Cost per year were as follows: new hospitali-
zations 76%, drug prescriptions 16%, visits/examinations 8%. ConClusions: Real 
world evidence in HF provides findings different from randomized clinical trials. 
Patients are older and more frequently females. Rate of use of treatments is not 
optimal. All-cause mortality remains high and re-hospitalizations are frequent. 
In nearly half cases, re-hospitalizations are due to non CV reasons, documenting 
relevant role of advanced age and co-morbidities. Costs for NHS are mainly driven 
by hospital costs.
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objeCtives: Atrial Fibrillation (AF) is the most common arrhythmia in Europe. AF 
increases the risk of death and cost of care, and is the second leading risk factor 
for stroke. The study objective was to estimate healthcare resource utilization 
(HCRU) and treatment costs of non-valvular AF (NVAF) patients with and without 
stroke. Methods: Retrospective cohort study of patients newly diagnosed with 
NVAF from January 2003 to December 2013. Patients were identified using medical 
diagnoses (ICD-9 codes) and treatment prescriptions (ATC codes) in the Badalona 
Serveis Assistencials database. HCRU included overall hospital admissions, out-
patient consultations, home-based care, laboratory tests, and pharmacological 
treatments. Differences in annualized total cost rates (95% CIs) per patient were 
calculated in € (2014 tariffs) by estimating HCRU in propensity-score matched 
cohorts of NVAF patients with and without stroke. Results: Overall, 3,052 
patients with NVAF were identified in the study period, and 11.2% had at least one 
stroke event after NVAF diagnosis. Median follow-up time of patients with stroke 
was 519 days. In the first year after stroke, there was on average an incremental 
0.9 hospital admissions per patient, 0.9 additional ER admissions, 2.9 additional 
hospital outpatient consultations, 5.7 additional consultations at other sites, 4.2 
additional procedures/laboratory tests, and 265 additional DDDs of anticoagulant. 
The incremental total cost of stroke per patient was 12,085€ (12,069-12,101) in the 
first year, and 6,384€ (6,377-6,391) for the entire follow-up period. Total cost of 
stroke per patient was 4.4 times higher than non-stroke patients during the first 
year after stroke, and 2.9 times higher for the entire follow-up. ConClusions: 
In Spain, NVAF patients with stroke consumed additional HCRU and treatment 
costs compared to patients without stroke. The burden of stroke was particularly 
important in the first year after stroke, and hospitalizations were the main drivers 
of the increased HCRU and costs.
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objeCtives: To investigate the resources used by ischemic stroke patients when 
hospitalized, and examine this relationship by stroke severity. Comparing a bot-
tom-up costing approach with national top-down costs. Methods: Data from five 
Belgian hospitals were requested for the years 2008 up to 2011 detailing the length-
of-stay (LOS), drugs, medical imaging and clinical biology tests. Participating hospi-
tals were distributed across the country and included regional as well as teaching 
hospitals. Severity of the stroke was defined as mild, moderate, major or severe 
according to the Severity-of-Illness (SOI) categorization within APR-DRG category 
045, which is determined by the classification of primary and secondary diagnoses. 
Average bottom-up costs were compared to the national reimbursement received 
by hospitals. Results: 2,496 hospital admissions were included in our analysis; all 
admissions contributed to the LOS calculations, 2,364 observations were available 
for medical imaging, 1,954 for drug treatments whereas data for clinical biology 
